Author: Brzycki, Marthilde; Richard, Robert; Burwick, Nicholas; Graf, Solomon; O'Brien, Craig; Wu, Daniel; Chauncey, Thomas R.
Title: Autologous hematopoietic transplantation following COVIDâ€19 infection Cord-id: ukliwk98 Document date: 2021_1_3
ID: ukliwk98
Snippet: Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVIDâ€19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.
Document: Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVIDâ€19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.
Search related documents:
Co phrase search for related documents- active coronavirus and acute symptom: 1
- active coronavirus infection and acute infection: 1, 2, 3, 4, 5, 6, 7, 8
- active therapy and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- active therapy and long term effect: 1
- active virus and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date